Best Practices in the Management of Metastatic Colorectal Cancer (mCRC): Expert Perspectives on an Evolving Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bayer Healthcare & Merck Sharp & Dohme Corp.

Description:
Colorectal cancer is the development of cancer from the colon or rectum. People with colorectal cancers that have not spread to distant sites usually have surgery as the main or first treatment. However, for patients with disease that has spread, or become metastatic, surgery is unlikely to cure the disease, and other treatments must be considered, including chemotherapy and targeted therapies, both alone and in combination. Metastatic colorectal cancer (mCRC) carries a poor prognosis, with a 5-year survival rate of approximately 70% for regional metastases and 13% for distant metastases. However, the prognosis of patients with mCRC has significantly improved in recent years with the introduction of inhibitors of the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways. Additionally, new treatments have just become available for patients with mCRC that has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, giving yet another important option in the evolving management of mCRC.

Upon completion of this activity, participants will be able to:

  • Analyze the efficacy and safety profiles of VEGF, EGFR and NTRK targeted agents and immune checkpoint inhibitors in the treatment of metastatic colorectal cancer (mCRC)

  • Discuss the evolving role of immune checkpoint inhibitors in the management of MSI-high mCRC

  • Examine the role of NTRK gene fusion and impact of NTRK gene fusion/TRK testing in treatment algorithms in mCRC

  • Assess the role of molecular biomarkers in selecting appropriate targeted agents for patients with mCRC in the clinical setting, as well as the roles of additional patient-driven factors, such as age, gender, and HRQOL

  • Identify patients with mCRC for whom a targeted therapy or immunotherapy is an appropriate choice for the next step in the management of their cancer

  • Anticipate and manage adverse events associated with the targeted therapy or immunotherapy indicated for the treatment of patients with mCRC in order to maximize tolerability and adherence to therapeutic regimens
     

Faculty: Richard Kim, MD
Medical Oncologist, Gastrointestinal Oncology Department
Moffitt Cancer Center
Assistant Professor of Oncology
University of South Florida, College of Medicine

Disclosure:

Dr. Kim serves on an advisory board for Bristol-Myers Squibb, Bayer, and Eisai. He serves as a consultant for Bayer and QED. He has received grant/research support from Bayer, Bristol-Myers Squibb, Eisai, and Janssen. He serves on the speaker's bureau for Lilly. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bayer Healthcare & Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue